Question to the Department of Health and Social Care:

To ask His Majesty's Government whether the forthcoming national cancer plan for England will consider expanding access to non-genomic biomarker testing, in addition to genomic testing, to determine eligibility for cancer precision medicines.

The Department is currently developing the National Cancer Plan for England, which will be published shortly. The plan will build on the commitment in the 10-Year Health Plan to provide comprehensive molecular profiling of all cancers. Genomic testing is a key element of molecular profiling.

We also recognise the important role that nongenomic biomarkers play in identifying the most effective treatments for individual patients. The plan will consider how to ensure access to high-quality treatment, including access to testing that determines eligibility for precision testing.